Status:

TERMINATED

Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS

Lead Sponsor:

University of Rochester

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

Several investigations have suggested that polyunsaturated fatty acids may promote therapeutic effects in MS. This pilot study will determine whether omega-6 polyunsaturated fatty acids (PUFAs),in the...

Detailed Description

Participants who meet inclusion criteria will start placebo treatment by taking olive oil for 2 months. This period will include screening activities including 3 monthly MRIs. Those with 2 enhancing l...

Eligibility Criteria

Inclusion

  • Relapsing MS
  • treated with FDA-approved dosage of interferon-beta (Avonex,Betaseron,Rebif), glatiramer acetate for at least 6 months OR no immunotherapy for at least 3 months
  • at least one clinical exacerbation or at least one gadolinium enhancing lesion on brain MRI in the past 12 months
  • at least two gadolinium enhancing lesions on three brain MRIs obtained during the placebo run-in period
  • women of childbearing potential may participate provided that they are using adequate birth control methods for the duration of the study. Women of childbearing potential must have a negative pregnancy test at baseline and be non-lactating.
  • willing and able to provide informed consent

Exclusion

  • corticosteroids within 1 month prior to screening
  • treatment with other immunotherapies (other than interferon-beta, glatiramer acetate or sporadic corticosteroids) within 3 months prior to screening
  • any significant medical condition or laboratory abnormality which may interfere with the subject's ability to participate in the study, including peptic ulcer disease, avascular necrosis and hepatic insufficiency
  • history of hypersensitivity or intolerability to vegetable oils or their constituents
  • unable to perform any of the required study procedures

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2012

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT00638196

Start Date

March 1 2008

End Date

September 1 2012

Last Update

August 11 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Rochester

Rochester, New York, United States, 14642